All In Biotech

Drug Trial Radar · NCT04820686

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects With Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

65

Actual

Start

May 7, 2021

Primary completion

Mar 30, 2023

Study completion Mar 30, 2023

Sponsor

Lead sponsor
Assembly BiosciencesIndustry
Sponsor type
Industry
Collaborators
Arbutus Biopharma Corporation
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

Conditions

  • Chronic Hepatitis B

Interventions

  • VBRDrug

    VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).

  • AB-729Drug

    AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.

  • SOC NrtIDrug

    Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With One or More Adverse Events (AEs)Time frame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.
  2. Number of Participants With Premature Treatment Discontinuation Due to AEsTime frame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.
  3. Number of Participants With One or More Abnormal Laboratory ResultTime frame: Laboratory results were collected from the time of signing the informed consent until the study was early terminated, up to 96 weeks.

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Saint Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Saint George Hospital - Australia

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Footscray Hospital

    Footscray, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Melbourne Health

    Parkville, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Acibadem City Clinic Tokuda Hospital

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment St. Ivan Rilski

    Sofia, Bulgaria

  • Nov Rehabilitatsionen Tsentar EOOD

    Stara Zagora, Bulgaria

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Sofia-Grad, Bulgaria

  • Centre Hospitalier Université de Québec - Université Laval

    Québec, Canada

  • Vancouver Infectious Disease Centre

    Vancouver, British Columbia, Canada

  • Pacific Gastroenterology Associates

    Vancouver, British Columbia, Canada

  • University Hospital - London Health Sciences Centre

    London, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Toronto Liver Centre

    Toronto, Ontario, Canada

  • Auckland Clinical Studies

    Auckland, New Zealand

  • Wellington Regional Hospital

    Wellington, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.